Farmer unions, including BKS, today demanded that the Environment Ministry cancel the meeting of the regulatory body GEAC scheduled for February 5 to discuss the much-debated genetically modified (

Indian scientists must develop domestic genetically modified crops rather than rely on unsuitable foreign technology.

Original Source

I have posed 50 questions each to the founders of 50 young Indian biomedical firms that are less than 5 years old. The questions were on the following themes: the backgrounds of the founders and their employees, the area of work of the company, its location and incubation experience, its funding and expenditure, its IP and licensing, its clients, and its risks and challenges. Several are doing pioneering work and the overall picture is impressive. The country should become a source of appropriate, high quality and affordable biomedical products and services in a few year.

Making its suggestions to the latest draft text of the Paris climate agreement, India on Monday pitched for inserting specific paragraph on the issue of finance and transfer of technology in the te

The year 2015 may well go down as a landmark year, with the adoption of the Sustainable Development Goals (SDGs) and some agreements at the Conference of Parties (COP) 21. Expectations from both are huge. Knowledge exchange and transfer will be key for achieving the expectations of both.

Clears Rs 1,500 cr SCRIPS project, Biju Expressway

Even as India-US trade (in both goods and services) has progressed towards the $100 billion mark, 2013-14 witnessed the emergence of a number of issues which adversely impacted the climate for bilateral trade and investment. Of these, none has been more contentious than the question of India’s IPR regime for pharmaceutical products.

The G20 leaders summit in Turkey in mid-November will hold the key to the success of the Paris climate talks a fortnight later as the richer ones among these 20 big economies are then expected to c

A new trade agreement being negotiated between 12 countries has come under fire from health campaigners who say it will push up drug prices and weaken health services.

The much hyped ‘stand off’ between US and India on India’s current IPR regime and concerns expressed that India is not fully compliant with TRIPS Agreement is more a myth than a reality. The differences are relatively minor and even though India is in the Priority Watch List of USTR, it is more of an internal alert system within US with no relevance to India or her position in the global trading community or the WTO. In fact, U.S.

Pages